Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Nephrology beyond JASN
You have accessRestricted Access

Endothelial Cell Dysfunction—Can One Outsmart Oxidative Stress by Direct Interaction with the Pathological Oxidized or Heme-Free Soluble Guanyl-Cyclase?

Targeting the Heme-Oxydized Nitric Oxide Receptor for Selective Vasodilatation of Diseased Blood Vessels. J Clin Invest 116: 2552–2561, 2006

J.-P. Stasch, P.M. Schmidt, P.I. Nedvetsky, T.Y. Arun Nedvetskaya, H.S. Kumar, S. Meurer, M. Deile, A. Taye, A. Knorr, H. Lapp, H. Müller, Y. Turgay, C. Rothkegel, A. Tersteegen, B. Kemp-Harper, W. Müller-Esterl and H. Schmidt
JASN March 2007, 18 (3) 663-669; DOI: https://doi.org/10.1681/ASN.2007010103
J.-P. Stasch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.M. Schmidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.I. Nedvetsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T.Y. Arun Nedvetskaya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.S. Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Meurer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Deile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Taye
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Knorr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Lapp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Müller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Turgay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Rothkegel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Tersteegen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Kemp-Harper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Müller-Esterl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Schmidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Figure1

Eberhard Ritz Feature Editor

It is well known that the rate of CV death is excessive in renal patients (1), but the underlying causes have not been completely resolved. Endothelial dysfunction, however, is thought to play a central role. One indicator of endothelial dysfunction, endothelial cell-dependent vasodilatation, was found by some (2,3), but not all, investigators to be impaired. Endothelial cells produce the vasodilator and vasoprotective molecule nitric oxide (NO), but in pathologic states the bioavailability of NO is reduced because the endothelial isoform of NO synthase (eNOS or NOSIII) is dysfunctional and generates reactive oxidant species—probably a phylogenetically ancient host defense reaction (4). Oxidative stress has been well documented in renal disease (5); specifically, nitrotyrosine, a footprint of oxidative stress, has been demonstrated in the vasculature (6).

To understand the rationale that led to the development of the compound 4-[((4-carboxybutyl){2-[(4-phenethyl-benzyl)oxy]phenylethyl}amino)methyl[benzoic]acid (BAY 58-2667), some introductory comments may be useful. This novel compound targets a signaling cascade that goes awry under conditions of oxidative stress, which is present in many forms of endothelial dysfunction. The cascade then produces oxidant species that promote tissue damage and, to make matter worse, reduces the production of NO.

The cascade comprises the sequential operation of the following enzymes (7):

  • nitric oxide (NO) synthase (NOSIII)

  • soluble guanyl cyclase (sGC), producing cyclic guanosine monophosphate (cGMP)

  • cyclic GMP activated protein kinase (cGK)

The three NO synthase isoforms have a heme prosthetic group and require several cofactors: oxygen, NADPH, flavin mononucleotide, flavin adenine dinucleotide, calmodulin, and tetrahydrobiopterin (BH4). The NO synthases oxidize the guanidine nitrogen of L-arginine to L-hydroxy-arginine and subsequently to the gas NO and citrulline. In the presence of the above cofactors, the enzyme operates as an NO synthase; in the absence of BH4 (so-called “uncoupling”) it generates the highly reactive oxidant superoxide, which is further converted into hydroxyperoxide, hydroxyl radicals, and, by interaction with NO, into peroxynitrite.

The receptor for NO is the hemoprotein guanyl cyclase. Of the different membrane-bound or soluble cytosolic isoforms, the soluble isoform (sGC) is of interest in the following context. The heterodimer consists of α and β subunits with a ferrous (divalent iron Fe++) heme prosthetic group. The iron is liganded to histidin 105 of the β subgroup. When NO binds to the Fe++, the bond with histidine 105 is disrupted, which thus reverses the inhibition of the catalytic center and promotes the synthesis of cGMP. This mechanism explains why many known regulators of sGC were found to interact with the heme group as activators or inhibitors. Oxydation of the divalent Fe++ in the heme molecule inhibits the activation of sGC by NO (8).

The development of BAY 58-2667 had also benefited from recent insights into the mechanisms underlying nitrate tolerance (9). Since the seminal observation of Stewart (10), it has been known that nitroglycerin loses efficacy as time goes by in patients with angina pectoris. Although part of the phenomenon (pseudotolerance) is explained by compensatory retention of fluid and sympathetic activation in response to the vasodilating effect of nitroglycerin, two phenomena have been found to account for true tolerance: reduced liberation of NO from nitroglycerin (11) (of somewhat controversial in vivo relevance) and development of oxidative stress as a consequence of increased superoxide and peroxynitrite formation (9,11). Such oxidative stress (12) presumably explains why meta-analyses found increased cardiac morbidity with chronic use of nitrates (13). Reactive oxidant species oxidize the crucial cofactor of sGC, BH4; depletion of BH4 renders NOSIII dysfunctional (“uncoupling”) so that it releases superoxide instead of NO. Reactive oxidant species also scavenge NO and reduce the activity of sGC that contains heme, which acts as a NO receptor (14). Furthermore, superoxide and peroxynitrite also adversely affect intracellular cGMP downstream signaling (15) as indicated by diminished phosphorylation of the vasodilator stimulated phosphoprotein (VASP). Antioxidants restore nitroglycerin sensitivity and VASP phosphorylation.

In view of these adverse effects of oxidative stress, it was of considerable interest that the recently developed BAY 58-2667 is an NO-independent sGC activator that is active even under conditions of nitrate tolerance, a state of known oxidative stress (16). The outcome of the present study is compatible with the concept that BAY 58-2267 selectively activates sGC in a presumably NO-insensitive oxidized and/or heme-free state. The attraction of such a compound is that it would selectively target diseased vessels as present in cardiovascular and renal disease.

How did the authors arrive at this conclusion?

  • Protophorphyrin IX is known to bind to the heme pocket of sGC. With a standard recombinant preparation of sGC, the authors showed that BAY 58-2267, similar to protophorphyrin IX, activated sGC concentration dependently, even when the recombinant sGC was heme-free within the limitations of the methodology. Additional experiments suggested that both BAY 58-2267 and protoporphyrin IX bound either to an unoccupied heme pocket or a heme pocket after displacing weakly bound oxidized heme.

  • Because multiple isoforms of sGC are known, the potential relevance of BAY 58-2267 for vascular disease was examined. In endothelial cell cultures the authors demonstrated under basal conditions an increase of cGMP upon administration of the compound without any effect on cGMP breakdown by phosphodiesterases, which suggests increased production of cGMP and excludes effects on cGMP catabolism. To imitate oxidative stress, these cells were also incubated with a peroxynitrite donor. This maneuver decreased NO-stimulated sGC activity after stimulation with NO and diminished cGMP concentrations. Paradoxically, the response to BAY 58-2267 was even increased by pretreatment with peroxynitrite.

  • Apart from these results in acute studies, chronic studies showed that, in addition, prolonged exposure of endothelial cells to BAY 58-2267 caused an increase in the protein level of the heme-binding β1 subunit of sGC. The latter effect was not seen with known NO donors or NO sensitizers. The authors offered the plausible working hypothesis that BAY 58-2667 stabilized the β1 subunit of sGC, reducing its degradation under basal conditions. In addition, it also prevented its degradation via the proteasome pathway after exposure of sGC to oxidants such as methylene blue, presumably by stabilizing the conformation of the enzyme protein.

  • To provide a functional readout the authors then proceeded to study isolated precontracted blood vessels (rat aortic ring preparations) in the presence or absence of peroxynitrite. The result was relaxation in response to administration of acetylcholine or of BAY 58-2667. Predictably, peroxynitrite impaired the maximal response to acetylcholine. An NO donor produced complete relaxation in the untreated vessel, but the potency was strikingly decreased after pretreatment with peroxynitrite. In contrast, pretreatment with the oxidant peroxynitrite strikingly increased the potency of BAY 58-2667.

  • To prove the in vivo relevance of this finding the authors studied models of vascular disease; –as a model of hypertension: the spontaneously hypertensive rat (SHR) –as models of atherosclerosis: Watanabe heritable hyperlipidemic rabbits and ApoE−/− mice –as models of diabetic vessel disease: eg, mesocolon arteries from patients with type 2 diabetes

  • BAY 58-2667 improved relaxation and increased cGMP levels in the aortas of SHR.

  • In saphenous artery rings of Watanabe rabbits, BAY 58-2667 inhibited the contraction in response to phenylephrin more potently than in wild-type rabbits, while the conventional NO donor nitroprusside was similarly effective in the Watanabe and wild-type rabbits. This finding suggests that the effect of BAY 58-2667 is potentiated by oxidative stress. Analogous findings were obtained in precontracted aortas of ApoE−/− mice on high-fat diet.

  • Mesocolon arteries obtained during bypass surgery from diabetic patients were more potently relaxed by BAY 58-2667 than arteries of nondiabetic patients.

  • Finally, the authors showed in vivo that such vasorelaxation translated into blood pressure lowering: blood pressure decreased after oral administration of BAY 58-2667 in SHR and transgenic renin rats [TG(mRen2)27 rats] treated with N-nitro-L-arginine-methylester to inhibit NO synthase. At the end of the study the rats had also lower levels of B-type natriuretic peptide, creatinine, urea, and renin.

The potential importance of this observation resides in the fact that this novel drug selectively targets a state of the modified sGC that is prevalent under disease conditions as shown in several animal models and in human disease. This selectivity of action is explained by the fact that BAY 58-2667 targets the oxidized heme-free sGC. This novel drug may open the door for more selective and sophisticated diagnostic procedures as well as interventions in cardiovascular disease, and potentially renal failure as the authors rightly state. It is certainly a long way from preclinical studies to clinical use—but the perspectives are promising.

Footnotes

  • Address correspondence to: Prof. Eberhard Ritz, Department Internal Medicine, Division of Nephrology, Bergheimer Strasse 56a, D-69115 Heidelberg, Germany. Phone: 49-0-6221-601705 or 49-0-6221-189976; Fax: 49-0-6221-603302; E-mail: Prof.E.Ritz{at}t-online.de

  • © 2007 American Society of Nephrology

References

  1. ↵
    Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35[Suppl 1] : S117 –S131, 2000
    OpenUrl
  2. ↵
    Morris ST, McMurray JJ, Rodger RS, Jardine AG: Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant 15 : 1194 –1200, 2000
    OpenUrlCrossRefPubMed
  3. ↵
    Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P: Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 16 : 959 –965, 2005
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Rabelink TJ, Luscher TF: Endothelial nitric oxide synthase: Host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 26 : 267 –271, 2006
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 : 1524 –1538, 2002
    OpenUrlCrossRefPubMed
  6. ↵
    Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K: The apolipoprotein e knockout mouse: A model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14 : 311 –316, 2003
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Murad F: Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 355 : 2003 –2011, 2006
    OpenUrlCrossRefPubMed
  8. ↵
    Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B: Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50 : 1 –5, 1996
    OpenUrlAbstract
  9. ↵
    Munzel T, Daiber A, Mulsch A: Explaining the phenomenon of nitrate tolerance. Circ Res 97 : 618 –628, 2005
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Stewart DD: Remarkable tolerance to nitroglycerin. Phila Polyclin 6 : 43 , 1888
    OpenUrl
  11. ↵
    Sage PR, de la Lande IS, Stafford I, Bennett CL, Phillipov G, Stubberfield J, Horowitz JD: Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation 102 : 2810 –2815, 2000
  12. ↵
    Warnholtz A, Mollnau H, Heitzer T, Kontush A, Moller-Bertram T, Lavall D, Giaid A, Beisiegel U, Marklund SL, Walter U, Meinertz T, Munzel T: Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol 40 : 1356 –1363, 2002
    OpenUrlCrossRefPubMed
  13. ↵
    Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C: Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 138 : 577 –585, 1999
    OpenUrlCrossRefPubMed
  14. ↵
    Weber M, Lauer N, Mulsch A, Kojda G: The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med 31 : 1360 –1367, 2001
    OpenUrlCrossRefPubMed
  15. ↵
    Mulsch A, Oelze M, Kloss S, Mollnau H, Topfer A, Smolenski A, Walter U, Stasch JP, Warnholtz A, Hink U, Meinertz T, Munzel T: Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 103 : 2188 –2194, 2001
  16. ↵
    Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F: NO- and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136 : 773 –783, 2002
    OpenUrlCrossRefPubMed

The Antisenescence Protein Klotho Is Necessary for FGF23-Induced Phosphaturia

It was almost one decade ago (1) that the klotho gene had been identified, but it does not fail to still spring surprises. Mice with a defect of klotho gene expression secondary to an insertional mutation disrupting the 5′ region develop a phenotype that reproduces not only individual features of human aging, but a complex spectrum of premature senescence: short lifespan, growth retardation, infertility, premature thymic involution, arteriosclerosis, skin atrophy, muscle atrophy, osteoporosis, pulmonary emphysema, ectopic calcification, motor neuron degeneration, cognition impairment, hearing disorder, and others (1). Conversely, overexpression of klotho extended the lifespan of mice (2). These observations suggest that the klotho gene acts as an aging suppressor gene. The link of the protein to the lifespan of mice led to the somewhat strange name “klotho.” Klotho was a Greek goddess, one of the three Parca, who was thought to spin the thread of life from her distaff onto her spindle. This mythology led Johannes Brahms to his famous romantic “Gesang der Parzen” (Schicksalslied; song of destiny).

The klotho gene is not only a determinant of premature senescence in mice. In humans as well, features related to senescence such as lifespan, osteoporosis, stroke, coronary disease are correlated to polymorphisms of the klotho gene (3,4). The klotho gene codes for a 130-kDa single-pass transmembrane protein with a short 10-amino acid cytoplasmic domain and a large extracellular domain that is shed and secreted into the blood (2,5). Although the Klotho protein is expressed in several tissues, the quantitatively most important site is the distal convoluted tubule in the kidney (1,6), but it is not yet certain whether Klotho acts in the kidney in a paracrine or endocrine fashion (in this case it would be another renal hormone).

How does klotho prolong lifespan? The klotho mouse with deficient klotho (klotho−/−) is hypoglycemic and extremely sensitive to insulin (7), whereas transgenic mice that overexpress klotho are insulin-resistant. Insulin resistance caused by genetic manipulation of insulin receptors or postreceptor steps is known to be associated with lifespan extension in a long list of species from Caenorhabditis elegans or Drosophila to mammalians such as the mouse (8).

A second feature of the Klotho mouse is increased oxidative stress (9). But in the context of the kidney, the relation of Klotho to mineral and vitamin D metabolism is of greatest interest. The FGF23 gene was originally identified as the gene mutated in autosomal dominant hypophosphatemic rickets (10,11). FGF23 codes for a phosphaturic hormone (11) that also accounts for other forms of hypophosphatemia (12) and is synthesized mainly by osteoblastic cells (13). The striking observation has been made that klotho knockout (1) and FGF23 knockout mice (14,15) share a great number of features such as short lifespan, growth retardation, hypogonadism, premature thymic involution, skin atrophy, muscle atrophy, arteriosclerosis, osteoporosis, pulmonary emphysema, soft tissue calcification, and, of particular interest in the context of the above study, hyperphosphatemia and increased 1,25(OH)2 D3 (14–16). FGF23 inhibits not only phosphate reabsorption in the proximal tubule, but also regulates the activities of the key enzymes controlling vitamin D metabolism in the kidney, ie, CYP27B1 (1α-hydroxylase) and CYP24A1 (24-hydroxylase) (17). FGF23 deficiency in contrast increases renal phosphate reabsorption and increases 1,25(OH)2 D3 (14,15). Simultaneous knockout of FGF23 plus 1α-hydroxylase abrogated hyperphosphatemia and tissue calcification and rescued many premature aging-like features of the FGF23 knockout mice (18). This observation suggests an important role of active vitamin D in the genesis of the FGF23 knockout phenotype (6,19). Previous studies have shown that FGF23 not only inhibits phosphate reabsorption via the sodium phosphate transporter (NaPi2a) in the brush border membranes of the proximal tubule, but also shares common signalling pathways with Klotho (20). The Klotho protein binds to multiple FGF receptors. Furthermore, the Klotho-FGF receptor complex binds FGF23 with higher affinity than the FGF receptor or Klotho alone, which suggests that FGF23 requires Klotho to activate FGF signalling, thus explaining why klotho knockout mice develop many features of the phenotype observed in FGF23 mice.

The above paper (21) now carries this issue one step further by clarifying in considerable detail the signalling pathways involved. In a nutshell they showed that the Klotho protein is required to convert a FGF receptor that interacts broadly with many FGF isoforms (a canonical receptor) into a receptor highly specific for FGF23. The authors discovered that injection of FGF23 into mice triggered early events in the kidney but not in other organs: phosphorylation of extracellular signal-regulated kinase (ERK) within the ultrashort period of 10 minutes; upregulation of the expression of early growth-responsive gene 1 (Egr1) was seen and used as a readout within 1 hour.

The authors now pursued several strategies. First, in homogenates of mouse kidney they tried to identify the molecule(s) directly binding to FGF23. To this end the homogenate was run through FGF23-Sepharose; matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry revealed that the protein bound was Klotho. When klotho was transiently expressed in Chinese hamster ovary (CHO) or other cells, high and low affinity binding sites for FGF23 emerged and the cells responded by phosphorylating ERK and upregulating Egr-1. As was already known, klotho knockout mice had elevated serum phosphate, 1,25(OH)2 D3, and calcium, as do FGF knockout mice. The authors now showed that–presumably in response to hyperphosphatemia–FGF23 concentrations were massively increased (ie, several thousand-fold) in the klotho knockout mice. This observation resembles the increased FGF23 concentration that is seen in uremic patients in response to phosphate retention (12). To strengthen the evidence, the authors used a complementary approach, and to this end they first produced a monoclonal antibody against the extracellular portion of mouse Klotho protein. The monoclonal antibody blocked the FGF23-induced increase in Egr-1 promoter activity as a readout in cells expressing Klotho. To prove that the monoclonal antibody against Klotho abrogated the interaction between FGF23 and Klotho in vivo, the monoclonal antibody was injected into wild-type mice. The vitamin D–regulating enzymes in the kidney changed in the direction seen in FGF23 knockouts (14,15): the mRNA for CYP27B1 increased and the mRNA for CYP24A1 decreased; in parallel with an increased abundance of the sodium–phosphate cotransporter (NaPi2a) in the renal brush border membranes, serum phosphate increased—possibly the result of increased 1,25(OH)2 D3—serum calcium increased as well. Thus, blocking Klotho with the monoclonal antibody reproduced the main features of the FGF23 knockout mouse, which indicates that interaction between Klotho and FGF23 is necessary for FGF23 to express its activity in the kidney.

The study thus identified another player in the genesis of the disturbed mineral metabolism of renal disease. The unfolding evidence indicates, in retrospect, that the simplifying assumption of the past, ie, that the disturbance of the mineral metabolism in renal failure was the result of abnormal phosphate and calcium concentration and balance (22), requires revision and sophistication in the light of findings obtained with the powerful methodologies available today.

References

  1. ↵
    Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45 –51, 1997
    OpenUrlCrossRefPubMed
  2. ↵
    Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M: Suppression of aging in mice by the hormone Klotho. Science 309 : 1829 –1833, 2005
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF, Becker LC, Dietz HC: KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 72 : 1154 –1161, 2003
    OpenUrlCrossRefPubMed
  4. ↵
    Yamada Y, Ando F, Niino N, Shimokata H: Association of polymorphisms of the androgen receptor and klotho genes with bone mineral density in Japanese women. J Mol Med 83 : 50 –57, 2005
    OpenUrlCrossRefPubMed
  5. ↵
    Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y: Secreted Klotho protein in sera and CSF: Implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565 : 143 –147, 2004
    OpenUrlCrossRefPubMed
  6. ↵
    Kuro-o M: Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 15 : 437 –441, 2006
    OpenUrlCrossRefPubMed
  7. ↵
    Utsugi T, Ohno T, Ohyama Y, Uchiyama T, Saito Y, Matsumura Y, Aizawa H, Itoh H, Kurabayashi M, Kawazu S, Tomono S, Oka Y, Suga T, Kuro-o M, Nabeshima Y, Nagai R: Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism 49 : 1118 –1123, 2000
    OpenUrlCrossRefPubMed
  8. ↵
    Kenyon C: The plasticity of aging: insights from long-lived mutants. Cell 120 : 449 –460, 2005
    OpenUrlCrossRefPubMed
  9. ↵
    Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, Kuro-o M: Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 280 : 38029 –38034, 2005
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26 : 345 –348, 2000
    OpenUrlCrossRefPubMed
  11. ↵
    White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ: Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60 : 2079 –2086, 2001
    OpenUrlCrossRefPubMed
  12. ↵
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348 : 1656 –1663, 2003
    OpenUrlCrossRefPubMed
  13. ↵
    Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112 : 683 –692, 2003
    OpenUrlCrossRefPubMed
  14. ↵
    Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 : 561 –568, 2004
    OpenUrlCrossRefPubMed
  15. ↵
    Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B: Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23 : 421 –432, 2004
    OpenUrlCrossRefPubMed
  16. ↵
    Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y: Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17 : 2393 –2403, 2003
    OpenUrlCrossRefPubMed
  17. ↵
    Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19 : 429 –435, 2004
    OpenUrlCrossRefPubMed
  18. ↵
    Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B: Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20 : 720 –722, 2006
    OpenUrlCrossRefPubMed
  19. ↵
    Yoshida T, Fujimori T, Nabeshima Y: Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 143 : 683 –689, 2002
    OpenUrlCrossRefPubMed
  20. ↵
    Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281 : 6120 –6123, 2006
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 : 770 –774, 2006
    OpenUrlCrossRefPubMed
  22. ↵
    Slatopolsky E, Gradowska L, Kashemsant C, Keltner R, Manley C, Bricker NS: The control of phosphate excretion in uremia. J Clin Invest 45 : 672 –677, 1966
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 18 (3)
Journal of the American Society of Nephrology
Vol. 18, Issue 3
March 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Endothelial Cell Dysfunction—Can One Outsmart Oxidative Stress by Direct Interaction with the Pathological Oxidized or Heme-Free Soluble Guanyl-Cyclase?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Endothelial Cell Dysfunction—Can One Outsmart Oxidative Stress by Direct Interaction with the Pathological Oxidized or Heme-Free Soluble Guanyl-Cyclase?
J.-P. Stasch, P.M. Schmidt, P.I. Nedvetsky, T.Y. Arun Nedvetskaya, H.S. Kumar, S. Meurer, M. Deile, A. Taye, A. Knorr, H. Lapp, H. Müller, Y. Turgay, C. Rothkegel, A. Tersteegen, B. Kemp-Harper, W. Müller-Esterl, H. Schmidt
JASN Mar 2007, 18 (3) 663-669; DOI: 10.1681/ASN.2007010103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Endothelial Cell Dysfunction—Can One Outsmart Oxidative Stress by Direct Interaction with the Pathological Oxidized or Heme-Free Soluble Guanyl-Cyclase?
J.-P. Stasch, P.M. Schmidt, P.I. Nedvetsky, T.Y. Arun Nedvetskaya, H.S. Kumar, S. Meurer, M. Deile, A. Taye, A. Knorr, H. Lapp, H. Müller, Y. Turgay, C. Rothkegel, A. Tersteegen, B. Kemp-Harper, W. Müller-Esterl, H. Schmidt
JASN Mar 2007, 18 (3) 663-669; DOI: 10.1681/ASN.2007010103
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Metabolic Syndrome—What We Know and What We Don't Know
  • Cardiovascular Events and Parathyroid Hormone—Suggestion of a Further Link
Show more Nephrology beyond JASN

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire